Hyppää sisältöön
    • FI
    • ENG
  • FI
  • /
  • EN
OuluREPO – Oulun yliopiston julkaisuarkisto / University of Oulu repository
Näytä viite 
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
  •   OuluREPO etusivu
  • Oulun yliopisto
  • Avoin saatavuus
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Therapeutic perspectives for the clinical application of umbilical cord hematopoietic and mesenchymal stem cells : overcoming complications arising after allogeneic hematopoietic stem cell transplantation

Gudauskaitė, Greta; Kairienė, Ignė; Ivaškienė, Tatjana; Rascon, Jelena; Mobasheri, Ali (2022-08-23)

 
Avaa tiedosto
nbnfi-fe2023070689155.pdf (225.6Kt)
nbnfi-fe2023070689155_meta.xml (37.31Kt)
nbnfi-fe2023070689155_solr.xml (39.37Kt)
Lataukset: 

URL:
https://doi.org/10.1007/5584_2022_726

Gudauskaitė, Greta
Kairienė, Ignė
Ivaškienė, Tatjana
Rascon, Jelena
Mobasheri, Ali
Springer Nature
23.08.2022

Gudauskaitė, G., Kairienė, I., Ivaškienė, T., Rascon, J., Mobasheri, A. (2022). Therapeutic Perspectives for the Clinical Application of Umbilical Cord Hematopoietic and Mesenchymal Stem Cells: Overcoming Complications Arising After Allogeneic Hematopoietic Stem Cell Transplantation. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 18. Advances in Experimental Medicine and Biology(), vol 1409. Springer, Cham. https://doi.org/10.1007/5584_2022_726

https://rightsstatements.org/vocab/InC/1.0/
© 2022 Springer Nature Switzerland AG. This version of the article has been accepted for publication, after peer review (when applicable) but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/5584_2022_726. Use of this Accepted Version is subject to the publisher’s Accepted Manuscript terms of use https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms.
https://rightsstatements.org/vocab/InC/1.0/
doi:https://doi.org/10.1007/5584_2022_726
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi-fe2023070689155
Tiivistelmä

Abstract

This review focuses on the therapeutic features of umbilical cord blood (UCB) cells as a source for allogeneic hematopoietic stem cell transplantation (aHSCT) in adult and child populations to treat malignant and nonmalignant hematologic diseases, genetic disorders, or pathologies of the immune system, when standard treatment (e.g., chemotherapy) is not effective or clinically contraindicated. In this article, we summarize the immunological properties and the advantages and disadvantages of using UCB stem cells and discuss a variety of treatment outcomes using different sources of stem cells from different donors both in adults and pediatric population. We also highlight the critical properties (total nucleated cell dose depending on HLA compatibility) of UCB cells that reach better survival rates, reveal the advantages of double versus single cord blood unit transplantation, and present recommendations from the most recent studies. Moreover, we summarize the mechanism of action and potential benefit of mesenchymal umbilical cord cells and indicate the most common posttransplantation complications.

Kokoelmat
  • Avoin saatavuus [38865]
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen
 

Selaa kokoelmaa

NimekkeetTekijätJulkaisuajatAsiasanatUusimmatSivukartta

Omat tiedot

Kirjaudu sisäänRekisteröidy
oulurepo@oulu.fiOulun yliopiston kirjastoOuluCRISLaturiMuuntaja
SaavutettavuusselosteTietosuojailmoitusYlläpidon kirjautuminen